A Pilot Study of Intranasal Lidocaine in Acute Management of Pediatric Migraine

Migraine in Children Clinical Trial

Official title:

A Pilot Study of Intranasal Lidocaine in Acute Management of Pediatric Migraine and Migraine-like Headache: A Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03806595
• Other study ID #: H18-03801
• Status: Completed
• Phase: Phase 1
• Start date: July 3, 2019
• Est. completion date: December 3, 2020

Study information

• Verified date: April 2021
• Source: University of British Columbia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Headaches in children are very common and are a source of significant distress for the patient and their family. Migraines are the most common headache disorder in children and are associated with episodic pain and other symptoms such as nausea and sensitivity to light and sound that can impair a child's ability to participate in daily activities and lead to missed school or parental missed work. When home treatment fails to relieve symptoms, children often seek care in the emergency department (ED) where a limited number of treatment options exist; while largely effective, these rescue treatments currently all require needle insertion of an intravenous line, take time to administer, result in prolonged ED stays, and have potential unpleasant side effects. In adult patients, a number of studies suggest that lidocaine, a local anesthetic administered intranasally, may provide relief of migraine and migraine-like headache pain in minutes. This approach has the benefit of working quickly, not requiring a needle, and having fewer side effects as the medication acts locally on nerves in the nose. Intranasal lidocaine has not yet been studied in children for this purpose. This study will compare the use of intranasal lidocaine to placebo. The goal of this pilot study is to provide information to inform the sample size calculation for the definitive randomized controlled trial that will aim to measure the efficacy of intranasal lidocaine as an analgesic option for children age 7 years and older who present to the Pediatric ED with a chief complaint of migraine or post traumatic headache with migraine-like features. Secondary objectives will be to report on the frequency and severity of rebound headache between the two treatment groups, adverse events of the study drug, as well as the impact on healthcare utilization measures.The investigators hypothesize that children receiving intranasal lidocaine will have faster and more effective pain recovery compared to children receiving placebo and will be less likely to require the standard therapy for migraine headache. Given very few side effects reported in adult studies and the relatively benign nature of those reported, the investigators do not expect any major safety concerns in the study. It is also hypothesized that intranasal lidocaine will lead to shorter ED visits, thus reducing use of staff and hospital resources and saving money for the healthcare system as a whole.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 3, 2020
• Est. primary completion date: December 3, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 7 Years to 16 Years

Eligibility

Inclusion Criteria:

1. Children aged 7-16 years

2. Migraine headache fulfilling Irma's criteria:

• Headache lasting 1-72 hours with at least 4 out of 6 of the following features:
• Moderate to severe episode of impaired daily activities
• Focal localization of headache
• Pulsatile description
• Nausea or vomiting or abdominal pain
• Photophobia, phonophobia, or avoidance of light and noise, or
• Symptoms increasing with activity or resolving by rest.

OR:

3. Post-traumatic headache as per ICHD-3 (beta edition) definition with migraine-like features (see above): A) Any headache fulfilling criteria C and D B) Traumatic injury to the head has occurred C) Headache is reported to have developed within 7 days after one of the following: i. The injury to the head, ii. Regaining of consciousness following the injury to the head, iii. Discontinuation of medication(s) that impair ability to sense or report headache following the injury to the head D) Headache persists for > 3 months after the injury to the head E) Not better accounted for by another ICHD-3 diagnosis

4. Verbal report of a pain score of 4 or greater on a 10 point numeric pain score (range 0-10 with increasing severity, i.e. 0 = no pain and 10 = most severe pain) after receiving first line therapy (non-narcotic analgesia) in either the out-patient or PED setting

5. Normal vital signs for age

6. Normal neurological exam (no focal deficits or abnormalities)

Exclusion Criteria:

1. Families not providing informed consent or assent, where appropriate

2. History of acute trauma or seizure in the preceding 24 hours

3. Clinical suspicion of or known intracranial pathology or underlying central nervous system disease

4. Headache associated with fever or meningismus

5. Known allergy/sensitivity to lidocaine

Related Conditions & MeSH terms

• Headache
• Migraine Disorders
• Migraine in Children
• Post-Traumatic Headache
• Posttraumatic Headache

Intervention

Drug:
• Lidocaine 2% Injectable Solution
The Barre method of intranasal administration will be used to instil 1mL of lidocaine 2% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
• Normal Saline Flush, 0.9% Injectable Solution
The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.

Locations

Country	Name	City	State
Canada	BC Children's Hospital	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in migraine pain	The primary outcome measure will be the proportion of subjects with numeric pain scores of < 4 out of 10 on a verbal rating scale (range 0 -10 with increasing severity, i.e. 0 = no pain and 10 = most severe pain).Treatment success is defined as a score of 3 or less at the two time points. This will be recorded for each patient during the study timeframe, until study completion.	Pain scores will be measured at 30 and 60 minutes post intranasal administration of either the study drug or placebo.
Secondary	Rebound headache	Proportion of patients with rebound headache (i.e. headache with pain score of greater than or equal to 4 out of 10 on a verbal rating scale; range 0 -10 with increasing severity, i.e. 0 = no pain and 10 = most severe pain). This will be recorded for each patient at the visit of interest during the study timeframe, until study completion.	Pain scores will be recorded at 60 minutes, 24 hours, and within 48-72 hours post intranasal therapy.
Secondary	Emergency department length of stay	Number of hours in the Emergency Department from time of registration to time of discharge or admission to hospital for each subject.	The emergency department length of stay will be ascertained from the medical record within 24 hours of the participant's visit.
Secondary	Proportion of participants discharged vs. admitted from the emergency department (emergency department disposition)	Disposition of the patient from the emergency department for the visit of interest only, i.e. discharge home, hospital admission. This will be recorded for each patient during the study timeframe, until study completion.	Disposition will be ascertained from the medical record within 24 hours of the participant's ED visit.
Secondary	Proportion of participants with a return visit to the emergency department within 72 hours of discharge.	Returns to the emergency department for similar complaints of migraine headache or posttraumatic headache with migraine like features.	Within 3 days from index visit.